TY - JOUR
T1 - Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent
AU - Dewi, Novriana
AU - Yanagie, Hironobu
AU - Zhu, Haito
AU - Demachi, Kazuyuki
AU - Shinohara, Atsuko
AU - Yokoyama, Kazuhito
AU - Sekino, Masaki
AU - Sakurai, Yuriko
AU - Morishita, Yasuyuki
AU - Iyomoto, Naoko
AU - Nagasaki, Takeshi
AU - Horiguchi, Yukichi
AU - Nagasaki, Yukio
AU - Nakajima, Jun
AU - Ono, Minoru
AU - Kakimi, Kazuhiro
AU - Takahashi, Hiroyuki
N1 - Funding Information:
This work was supported in part by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Sport and Culture, Japan (No. 21659316 and 23659639 to Hironobu Yanagie). A part of results were obtained by the common use of nuclear facilities of Japan Atomic Energy Agency, Tokaimura, Ibaraki, Japan.
PY - 2013/7
Y1 - 2013/7
N2 - Neutron capture therapy (NCT) is a promising non-invasive cancer therapy approach and some recent NCT research has focused on using compounds containing gadolinium as an alternative to currently used boron-10 considering several advantages that gadolinium offers compared to those of boron. In this study, we evaluated gadolinium-entrapped liposome compound as neutron capture therapy agent by in vivo experiment on colon-26 tumor-bearing mice. Gadolinium compound were injected intravenously via tail vein and allowed to accumulate into tumor site. Tumor samples were taken for quantitative analysis by ICP-MS at 2, 12, and 24h after gadolinium compound injection. Highest gadolinium concentration was observed at about 2h after gadolinium compound injection with an average of 40.3μg/g of wet tumor tissue. We performed neutron irradiation at JRR-4 reactor facility of Japan Atomic Energy Research Institute in Tokaimura with average neutron fluence of 2×1012 n/cm2. The experimental results showed that the tumor growth suppression of gadolinium-injected irradiated group was revealed until about four times higher compared to the control group, and no significant weight loss were observed after treatment suggesting low systemic toxicity of this compound. The gadolinium-entrapped liposome will become one of the candidates for Gd delivery system on NCT.
AB - Neutron capture therapy (NCT) is a promising non-invasive cancer therapy approach and some recent NCT research has focused on using compounds containing gadolinium as an alternative to currently used boron-10 considering several advantages that gadolinium offers compared to those of boron. In this study, we evaluated gadolinium-entrapped liposome compound as neutron capture therapy agent by in vivo experiment on colon-26 tumor-bearing mice. Gadolinium compound were injected intravenously via tail vein and allowed to accumulate into tumor site. Tumor samples were taken for quantitative analysis by ICP-MS at 2, 12, and 24h after gadolinium compound injection. Highest gadolinium concentration was observed at about 2h after gadolinium compound injection with an average of 40.3μg/g of wet tumor tissue. We performed neutron irradiation at JRR-4 reactor facility of Japan Atomic Energy Research Institute in Tokaimura with average neutron fluence of 2×1012 n/cm2. The experimental results showed that the tumor growth suppression of gadolinium-injected irradiated group was revealed until about four times higher compared to the control group, and no significant weight loss were observed after treatment suggesting low systemic toxicity of this compound. The gadolinium-entrapped liposome will become one of the candidates for Gd delivery system on NCT.
UR - http://www.scopus.com/inward/record.url?scp=84880930693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880930693&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2012.11.010
DO - 10.1016/j.biopha.2012.11.010
M3 - Article
C2 - 23743325
AN - SCOPUS:84880930693
VL - 67
SP - 451
EP - 457
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
SN - 0753-3322
IS - 6
ER -